Non-classical HLA molecules should also be considered in the development of anti-tumor directed vaccination – and future preclinical developments will target the identification of tumor-associated antigens presented by non-classical MHC-molecules to anti-cancer directed immune cells including the non-classical Major histocompatibility complex class I-related (MR1) molecule (178). This evidence concerns the gene HLA-C and cancer.